Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs.
S
odium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs that reduce renal glucose reabsorption in the proximal convoluted tubule, leading to increased urinary glucose excretion (1) . The SGLT2 is a high-capacity, low-affinity transporter that is overexpressed and overactivated in patients with type 2 diabetes and is responsible for 80% to 90% of renal glucose reabsorption (2) . Current guidelines do not include SGLT2 inhibitors in treatment recommendations (3) . In 2011, a U.S. Food and Drug Administration (FDA) Advisory Committee voted against approval of dapagliflozin because of concerns about increased risk for bladder and breast cancer (4, 5) . The European Medicines Agency (EMA) recently approved dapagliflozin for treatment of type 2 diabetes, either as monotherapy or as add-on treatment (6) . In March 2013, the FDA approved canagliflozin for use in patients with type 2 diabetes (7, 8) .
Previous systematic reviews explored the efficacy and safety of SGLT2 inhibitors but focused primarily on studies comparing dapagliflozin with placebo, thus missing extension studies, comparative effectiveness trials, and studies assessing newer SGLT2 inhibitors (9, 10) . To update and clarify the evidence base of the efficacy and safety of SGLT2 inhibitors, we conducted a systematic review and meta-analysis, based on published and unpublished randomized trials of adult patients with type 2 diabetes, that compared SGLT2 inhibitors with placebo or other antidiabetic agents, either as monotherapy or as add-on treatment.
hand-searched abstracts from meetings of relevant associations (American Diabetes Association, European Association for the Study of Diabetes, International Diabetes Federation, and American Association of Clinical Endocrinologists) from 2009 to 2012 and, in 2013, scanned Web sites of relevant pharmaceutical companies, retrieved reports from regulatory authorities (FDA and EMA) (4, 6, 7) , and searched clinical trial registries (ClinicalTrials.gov). We perused reference lists of eligible articles and relevant reviews, including 2 systematic reviews (9, 10) . Finally, we conducted a rapid search of MEDLINE via PubMed in April 2013 using relevant keywords for long-term observational studies addressing potential harms or adverse effects.
Study Selection
We included randomized, controlled trials that compared an SGLT2 inhibitor with placebo or another antidiabetic medication in adults with type 2 diabetes. We included trials regardless of language, year of publication, or publication status. Publications retrieved from electronic databases were imported into reference management software. After deduplication, 2 reviewers independently screened titles and abstracts and subsequently examined the full text of potentially eligible reports. Two different reviewers independently screened reports retrieved from regulatory databases, conference abstracts, Web sites of pharmaceutical companies, and trial registries. Disagreements at each stage of selection were arbitrated by a third reviewer and resolved by consensus. Eligible reports were juxtaposed against each other to remove duplicates and maximize information yield.
Data Extraction and Risk-of-Bias Assessment
Data extraction was performed independently by 2 reviewers using a predesigned data collection form and was checked by a third reviewer. For each eligible trial, we extracted data on study characteristics, participants' baseline characteristics, and efficacy and safety outcomes. Efficacy outcomes included change from baseline in hemoglobin A 1c (HbA 1c ) level (primary outcome), body weight, and systolic and diastolic blood pressures. Clinical outcomes of interest included all-cause mortality and cardiovascular events (myocardial infarction, stroke, death due to cardiovascular disease, or hospitalization for unstable angina). Information about potential harms that was extracted included incidence of any hypoglycemia, urinary tract infections, genital tract infections, hypotension, any serious adverse event, bladder cancer, or breast cancer. Data about renal and bone safety and liver toxicity were taken from information in regulatory authorities' reports. Hypoglycemia and other safety outcome data were extracted on the basis of definitions used in each study.
Missing data were requested via e-mails to corresponding authors or pharmaceutical companies. Data from multiple reports for the same study were collated. In cases of contradictory material, we used data from regulatory documents and published articles rather than reports from conference abstracts or Web sites.
Two reviewers independently assessed risk of bias of each study using the Cochrane Collaboration risk-of-bias tool (14) (Supplement 2, available at www.annals.org). Disagreements were resolved by consensus. We explored risk of bias across studies (publication bias) by using the Egger statistical test (15) .
Data Synthesis, Grading of Evidence, and Analysis
We used the Grading of Recommendations Assessment, Development and Evaluation approach to summarize the strength of evidence and determine confidence in summary estimates for clinically relevant comparisons and outcomes (16, 17) . Three reviewers graded inconsistency, risk of bias, indirectness, imprecision, and publication bias for evidence related to each of the following outcomes: change in HbA 1c level, change in body weight, change in systolic blood pressure, incidence of hypoglycemia, incidence of cardiovascular events, and incidence of urinary and genital tract infections.
We conducted meta-analyses when 3 or more studies provided relevant data. For efficacy outcomes, we analyzed only trials of at least 12 weeks' duration. For safety outcomes, we used eligible trials regardless of duration of the intervention. In studies with extension periods, we used the report with the longest intervention. We calculated weighted mean differences (WMDs) and 95% CIs for continuous outcomes using an inverse variance random-effects model. For dichotomous outcomes, we calculated odds ratios (ORs) and 95% CIs by using the fixed-effects MantelHaenszel approach with a treatment group continuity correction for zero events, including trials with zero events in both groups. We verified robustness of findings across different methods (Peto OR; constant correction; or treatment group correction for continuity, including and excluding studies with zero events) (18) . For SGLT2 inhibitors that had received approval, we used data for patients randomly assigned to the highest available approved dose (5 or 10 mg for dapagliflozin and 100 or 300 mg for canagliflozin). For other SGLT2 inhibitors, we used data from the group allocated to the highest, most common dose. Data on incidence of all-cause mortality, any serious adverse event, cardiovascular events, bladder cancer, and breast cancer were extracted for all treatment groups regardless of SGLT2 inhibitor dose.
In our main analyses, we used only data published in journals or identified in regulatory authorities' reports and excluded data retrieved only from conference abstracts or Web sites. When available, data for intention-to-treat populations were used. We performed separate analyses for placebo-controlled trials and those with active controls and subgroup analyses for use of SGLT2 inhibitors as monotherapy or add-on treatment. We also conducted sensitivity analyses using data from all eligible trials regardless of information source. Heterogeneity was assessed with the I statistic, with values greater than 60% representing high heterogeneity (17) . We planned to explore heterogeneity with a sensitivity analysis that included only trials at low risk of bias for our primary outcome. Finally, we explored potential differences among individual SGLT2 inhibitors by conducting separate analyses for each substance when sufficient data were available. All statistical analyses were done using Stata, release 11.2 (StataCorp, College Station, Texas), and RevMan 5.2 (Nordic Cochrane Center, Copenhagen, Denmark [19] ).
Role of the Funding Source
This study received no funding.
RESULTS

Search Results and Study Characteristics
We found 49 primary and 9 extension studies that met eligibility criteria (Appendix Figure, available (20 -72) . Almost all were sponsored by pharmaceutical companies. Most trials had a double-blind design, except for 3 studies that had a double-blind primary phase (21, 23, 60) and an open-label extension phase (22, 24) . The SGLT2 inhibitors that were used included dapagliflozin (21 trials), canagliflozin (12 trials), ipragliflozin (8 trials), empagliflozin (3 trials), luseogliflozin (2 trials), tofogliflozin (1 trial), ertugliflozin (1 trial), and remogliflozin (1 trial). Sodium-glucose cotransporter 2 inhibitors were compared with placebo in 45 studies (n ϭ 11 232) and with active comparators in 13 studies (n ϭ 5175) as either monotherapy or add-on treatment. Among the 13 studies with active controls, SGLT2 inhibitors were compared with metformin in 6 studies (22, 23, 25, 30, 48) , sitagliptin in 5 studies (7, 59, 60, 62, 63) , and a sulfonylurea in 2 studies (43, 57) . Duration of the intervention ranged from 12 days to 104 weeks. Five studies had less than 12 weeks' duration, 32 studies lasted between 12 and 26 weeks, and 5 trials had a duration between 48 and 52 weeks. Study duration was at least 90 weeks in 7 studies. Mean HbA 1c level at baseline was available for 41 studies, ranged from 6.9% to 9.2%, and was balanced between treatment groups.
Patients with severe renal impairment were excluded in almost all studies, except for 1 canagliflozin trial (55) . Dapagliflozin trials included 684 patients with moderate renal impairment (6) . Two canagliflozin trials allowed enrollment of patients with moderate renal impairment (34, 38) , whereas 1 dapagliflozin trial (52) and 1 canagliflozin trial (71) involved such patients exclusively. Three trials (42, 54, 55) recruited patients at high risk for cardiovascular disease.
Data Collection and Risk-of-Bias Assessment of Included Trials
We requested additional data for 2 published studies and 29 abstracts from corresponding authors or relevant pharmaceutical companies. Of these, 12 responded to our e-mails, but only 2 provided the requested data.
Overall risk of bias for the primary outcome was high in almost all studies, primarily because of incomplete outcome data (high discontinuation rate or use of inadequate imputation method to handle missing data) (Supplement 2). Attrition rates were high (Ն20%) or unbalanced between treatment groups in 14 studies and unclear in 26 studies (primarily reported as abstracts). The method of imputation of missing data was unclear in 11 studies identified in abstract form. In most published trials, postrescue data were excluded and missing data were imputed using a last-observation-carried-forward (LOCF) approach. The FDA report that was reviewed (4) included a sensitivity analysis on different imputation methods for 2 dapagliflozin trials (21, 36) . The analysis showed overstated results when the LOCF method was used. The Egger test did not reveal any evidence of publication bias (P ϭ 0.89).
Glycemic Efficacy
Compared with placebo, SGLT2 inhibitors reduced HbA 1c levels when used as monotherapy (WMD, Ϫ0.79% [95% CI, Ϫ0.96% to Ϫ0.62%]; I 2 ϭ 71%) or add-on treatment (WMD, Ϫ0.61% [CI, Ϫ0.69% to Ϫ0.53%]; I 2 ϭ 73%) (Figure 1 ). Compared with other hypoglycemic agents, SGLT2 inhibitors had similar glycemic efficacy when used as monotherapy (WMD, 0.05% [CI, Ϫ0.06% to 0.16%]; I 2 ϭ 0%) or add-on treatment (WMD, Ϫ0.16% [CI, Ϫ0.32% to 0.00%]; I 2 ϭ 82%) (Figure 2 ). When each SGLT2 inhibitor was analyzed separately, changes in HbA 1c level versus placebo were Ϫ0.59% (CI, Ϫ0.67% to Ϫ0.50%) for dapagliflozin and Ϫ0.78% (CI, Ϫ0.90% to Ϫ0.66%) for canagliflozin ( Table 1) .
Overall results were similar for both comparisons in sensitivity analyses that included all eligible studies regardless of information source (SGLT2 inhibitor vs. placebo WMD, Ϫ0.69% [CI, Ϫ0.78% to Ϫ0.61%; I 2 ϭ 84%]; SGLT2 inhibitor vs. active comparator WMD, Ϫ0.11% [CI, Ϫ0.21% to Ϫ0.01%; I 2 ϭ 59%]) (Figures 1 and 2 of Supplement 4, available at www.annals.org). We did not perform a sensitivity analysis that included only trials at low risk of bias because overall risk of bias was high for all studies.
Body Weight
Body weight was measured as absolute change from baseline in most trials; however, some trials reported only the percentage of change. Thus, we conducted separate analyses based on unit of measurement. in body weight. Of note, absolute body weight reduction for SGLT2 inhibitors versus other active comparators was less evident and heterogeneity was eliminated in a post hoc sensitivity analysis that excluded 1 sulfonylurea-controlled study (57) (Figure 8 of Supplement 4). Risk of bias was high for both systolic and diastolic blood pressure analyses.
Hypoglycemia
Incidence of hypoglycemia was low in most treatment groups, except for among patients receiving a sulfonylurea or insulin as allocation treatment or background therapy. The OR for any hypoglycemia with SGLT2 inhibitors was 1.28 (CI, 0.99 to 1.65; I 2 ϭ 0%) ( Table 1 and Figure 9 of Supplement 4) compared with placebo and 0.44 (CI, 0.35 to 0.54; I 2 ϭ 93%) (Figure 10 of Supplement 4) compared with other antidiabetic medications. However, exclusion of 1 sulfonylurea-controlled study (57) in a post hoc sensitivity analysis resulted in similar hypoglycemic risk compared with other antidiabetic agents and removed heterogeneity (OR, 1.01 [CI, 0.77 to 1.32]; I 2 ϭ 0%). Across all studies analyzed, severe hypoglycemia (defined as an episode requiring assistance from another person) was rare in all treatment groups and was seen primarily in participants already receiving a sulfonylurea.
Genitourinary Tract Infections and Hypotension
Urinary tract infections were more common among patients treated with SGLT2 inhibitors than among those receiving placebo (OR, 1.34 [CI, 1.03 to 1.74]; I 2 ϭ 0%) Results are from IV random-effects meta-analysis. IV ϭ inverse variance; SGLT2 ϭ sodium-glucose cotransporter 2. * Reference 48 includes 2 randomized trials of dapagliflozin at doses of 5 mg (study 1) and 10 mg (study 2).
Review 
Death and Serious Adverse Events
All-cause mortality did not differ between SGLT2 inhibitors and placebo or active comparators, although relatively few deaths have been reported in trials. Twenty-three deaths were reported among patients treated with SGLT2 inhibitors (n ϭ 5771), and 8 were reported among patients receiving either placebo (4 of 1738 patients) or an active comparator (4 of 1251 patients). The OR for any serious adverse event with SGLT2 inhibitors versus comparators was 0.90 (CI, 0.72 to 1.13; I 2 ϭ 0%) ( Table 1) .
Cardiovascular Outcomes
Our meta-analysis of cardiovascular outcomes for dapagliflozin, which was based on 14 trials (n ϭ 6300), yielded an OR of 0.73 (CI, 0.46 to 1.16; I 2 ϭ 0%) compared with control. This estimate was consistent with the FDA report and the more recent EMA report (hazard ratio [HR], 0.82 [CI, 0.58 to 1.15]). In a pooled analysis of 2 dapagliflozin trials in patients with established cardiovascular disease (42, 54) , the HR for the composite cardiovascular end point (cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina) was 1.07 (CI, 0.64 to 1.72) versus placebo (6).
Canagliflozin was not associated with an increased risk for the composite cardiovascular outcome compared with * Based on data from individual study reports and reports from the U.S. Food and Drug Administration Advisory Committee (4, 7) and European Medicines Agency (6). † We synthesized data when Ն3 studies provided relevant data. ‡ For change in HbA 1c level, body weight, and systolic and diastolic blood pressures, the effect estimate is the weighted mean difference, calculated using an inverse variance-weighted random-effects model. For the remaining outcomes, the effect estimate is the odds ratio, calculated using the fixed-effects Mantel-Haenszel approach with a treatment group continuity correction for zero events, including trials with zero events in both groups (18) . Effect estimates could not be calculated when data were based only on pooled analyses from regulatory authorities' reports and we could not reproduce data from the original trials. § Results from sensitivity analysis, excluding 1 sulfonylurea-controlled study (57) . Cardiovascular death, myocardial infarction, nonfatal stroke, or hospitalization for unstable angina.
placebo or active comparator on the basis of data from 10 trials that included a total of 10 474 patients (OR, 0.95 [CI, 0.71 to 1.26]; I 2 ϭ 0%), although CIs were wide. In the FDA report (7), the HR for nonfatal stroke was higher in patients receiving canagliflozin (6876 patient-years) than in the control groups (3470 patient-years) (HR, 1.46 [CI, 0.83 to 2.58]). In addition, an imbalance in incidence of cardiovascular events observed during the first 30 days of the dedicated cardiovascular trial (55) between canagliflozin (13 of 2886 patients) and placebo (1 of 1441 patients) resulted in an HR of 6.50 (CI, 0.85 to 49.66), possibly due to volume depletion after canagliflozin initiation. This imbalance was not evident after 30 days.
Bladder and Breast Cancer
For dapagliflozin, data on bladder and breast cancer that were retrieved from regulatory databases and other sources produced a pool of 5501 patients with at least 5000 patient-years of exposure who were treated with dapagliflozin and a total of 3184 patients with at least 2350 patient-years of exposure who received placebo or an active comparator (4, 6) . Nine cases of bladder cancer were identified in patients treated with dapagliflozin as opposed to 1 case in patients receiving placebo. All patients were men, with a median time of diagnosis of 399 days (range, 43 to 727 days). Baseline characteristics for bladder cancer risk factors were similar between dapagliflozin and placebo groups. As noted in the FDA report, included trials were not powered to distinguish statistically between the 9 cases and 1 case of bladder cancer; however, the observed event rate of 9 cases exceeds the expected rate of only 2 cases in an age-matched reference male population of patients with diabetes (4).
Breast cancer was reported in 9 women aged 53 to 74 years who were treated with dapagliflozin and in 1 patient in the control group. Study day of diagnosis ranged from day 6 to day 334, which is much shorter than the average of at least 5 years of exposure regarded as sufficient for breast cancer to be detectable (6) .
Data on cancer in patients treated with canagliflozin are based primarily on an FDA report (7) . A pooled analysis of 9 trials with approximately 8000 person-years of exposure did not show any difference in incidence of bladder cancer between canagliflozin (5 of 6648 patients) and control (4 of 3640 patients) groups. Similarly, incidence of breast cancer did not differ between canagliflozin (12 of 2827 patients) and comparators (6 of 1501 patients).
Renal and Bone Safety and Liver Toxicity
Data on renal and bone safety and liver toxicity were retrieved from regulatory authorities' reports (4, 6, 7) . In patients with moderate renal impairment, incidence of renal-related adverse events was increased with dapagliflozin and canagliflozin compared with placebo. In patients with normal or mildly impaired renal function, high doses of canagliflozin (300 mg) were associated with increased incidence of renal-related adverse events (14 of 834 patients) compared with placebo (4 of 646 patients).
In a pooled analysis, there was no imbalance in fractures between dapagliflozin and comparator groups (overall incidence, Ͻ1.6%). However, in patients with moderate renal impairment, incidence of fractures was higher in dapagliflozin recipients (4 and 8 events in the 5-and 10-mg groups, respectively) than in placebo recipients (no events). An updated safety analysis of canagliflozin trials noted a nonsignificant imbalance in fracture incidence in patients treated with canagliflozin compared with control patients. Regarding liver-related adverse events, regulatory authorities' reports concluded that slight imbalances among patients treated with dapagliflozin or canagliflozin and control groups were probably not associated with the study drug.
Grading of Evidence
Quality of evidence was downgraded to low for glycemic efficacy, percentage of change in body weight, incidence of any hypoglycemia, and cardiovascular outcomes because of high risk of bias and inconsistency or imprecision. Quality was downgraded to moderate for effect on systolic blood pressure, incidence of urinary and genital tract infections, and absolute change in body weight because of high or unclear risk of bias ( Table 2) .
DISCUSSION
Sodium-glucose cotransporter 2 inhibitors were associated with a 0.66% reduction in HbA 1c level and had glycemic efficacy similar to that of other antidiabetic agents. They also had a favorable effect on body weight and blood pressure. Risk for hypoglycemia was similar to that of metformin or sitagliptin and lower than that of sulfonylureas. Increased incidence of urinary and genital tract infections was probably due to glucosuria associated with the use of SGLT2 inhibitors. In patients with moderate renal impairment, use of dapagliflozin or high doses of canagliflozin was associated with increased incidence of renal-related adverse events. Data on cardiovascular outcomes and death were inconclusive. A numerical imbalance in nonfatal stroke events among patients treated with canagliflozin needs clarification and confirmation. We also noted a numerical imbalance of bladder and breast cancer cases between patients treated with dapagliflozin and control patients. The number of observed cases for these types of cancer exceeds the expected number of cases in the general diabetic population, as reported in epidemiologic reports (4). However, early detection after short exposure and potential detection bias due to frequent urinalysis mitigate against a causative relationship. Hence, no robust conclusions can be drawn pending accumulation of longterm data.
To our knowledge, this systematic review provides the most up-to-date and comprehensive summary of the benefits and risks of SGLT2 inhibitors as of April 2013. We identified 2 pertinent systematic reviews through a rapid search of MEDLINE. Musso and colleagues (10) documented the favorable effect of dapagliflozin on glycemic control, blood pressure, and weight on the basis of data retrieved before December 2010 from electronic databases and conference abstracts. Their meta-analysis included 13 placebo-controlled trials (primarily for dapagliflozin), 5 of which had a duration of less than 28 days. In a more recent systematic review, Clar and associates (9) examined the efficacy and safety of SGLT2 inhibitors in dual or triple antidiabetic therapy. Their search, which was done in July 2012, provided a total of 8 trials with a duration between 12 and 52 weeks, 7 of which were for dapagliflozin and 1 of which was for canagliflozin. Thus, conclusions from prior meta-analyses were based on a small number of trials of short duration that primarily compared dapagliflozin with placebo. Our review included a much larger number of both placebo-controlled trials and those with active controls, including extensions and studies for newer SGLT2 inhibitors, identified from multiple electronic databases and gray literature. We also used data from regulatory databases to summarize information about bladder and breast cancer, cardiovascular outcomes, liver toxicity, and renal and bone safety. Finally, we rated the overall strength of evidence using the Grading of Recommendations Assessment, Development and Evaluation approach. We acknowledge several limitations of the body of evidence and review process. Most included studies used LOCF methods to impute missing data, which can introduce significant bias into the results (73, 74) . The combination of LOCF imputation with exclusion of postrescue data can lead to overstated results, as noted in the FDA report for dapagliflozin (4) . Unfortunately, this approach to handling missing data was used in recently published trials of SGLT2 inhibitors (23, 25, 27, 34, 63, 70, 71) . Most studies received industry funding, which introduced further bias into the results (75) . No conclusions about differences among individual SGLT2 inhibitors could be made because of a lack of head-to-head trials. Results for cardiovascular outcomes, death, and incidence of cancer are based primarily on data from trials designed to assess short-term efficacy outcomes and should therefore be interpreted with caution. Limitations at the review level are related to the high degree of heterogeneity observed in HbA 1c ϭ hemoglobin A 1c ; SGLT2 ϭ sodium-glucose cotransporter 2. * Among studies that compared SGLT2 inhibitors with active comparators (any antidiabetic medication) in adults with type 2 diabetes mellitus. † The assumed risk is based on the median risk in the control group across studies. The corresponding risk is based on the assumed risk in the comparison group and the relative effect of the intervention. ‡ Evidence was graded using the Grading of Recommendations Assessment, Development and Evaluation guidelines (16, 17) . Evidence could be rated as high quality (further research is very unlikely to change our confidence in the estimate of effect), moderate quality (further research is likely to have an important effect on our confidence in the estimate of effect and may change the estimate), low quality (further research is very likely to have an important effect on our confidence in the estimate of effect and is likely to change the estimate), or very low quality (we are very uncertain about the estimate). § Lower change indicates better outcome. Downgraded for inconsistency due to heterogeneity of effect estimate. ¶ Downgraded because most of the studies had high risk of bias. ** The monotherapy subgroup included SGLT2 inhibitors as first-line antidiabetic treatment. The add-on therapy subgroup included SGLT2 inhibitors as add-on therapy to existing antidiabetic treatment. † † Downgraded because most of the studies had unclear risk of bias. ‡ ‡ Downgraded for imprecision due to wide CIs in results.
analyses of HbA 1c level, body weight, and incidence of hypoglycemia. We explained heterogeneity of body weight and hypoglycemia by sensitivity analyses excluding sulfonylurea-controlled trials. For HbA 1c level, heterogeneity could be attributed to a combination of factors, including differences in individual SGLT2 inhibitors, background antidiabetic treatment, or class of active comparator. Future research should explore differences among individual SGLT2 inhibitors and differences between SGLT2 inhibitors and other antidiabetic agents. We identified several ongoing trials, some of which have been designed to assess safety outcomes (Supplement 3). On completion, they are expected to provide adequate data to draw safer inferences about long-term safety and cardiovascular outcomes. Moreover, we identified 25 eligible completed trials that could not be included in our analysis because of undisclosed results (Supplement 3). Most of these trials were completed in 2012 and will probably be published in the near future. Incomplete reporting and inappropriate analysis plans are consistently criticized, and many organizations urge the need to rectify this problem (76) . Timely disclosure of trial results (77), judicious analysis plans (73, 74) , and access to raw data (78) are essential to ensure valid results and guide evidence-based therapeutic decision making. In the meantime, it seems justifiable for systematic reviews to include data from regulatory authorities in their information sources (79) .
In conclusion, SGLT2 inhibitors seem to be an effective treatment option for adults with type 2 diabetes. They may improve some short-term outcomes, but further research is necessary to clarify effects on long-term clinical outcomes, diabetic complications, and safety. 
